BioMarin acquires early-stage bone disease candidate in modest deal
BioMarin has struck another small acquisition to obtain an early-stage asset for bone disease, just a week after halting development of a rare disease drug from a $270 million purchase. The financial terms are reportedly similar to that previous deal. This move signals the company's continued focus on building its pipeline despite recent setbacks.
Related stories
Roche pays $190M upfront for Hanmi's muscle-sparing obesity drug · Drug development
Leo Pharma pays up to $435M for rights to Tanabe's oral therapy for sun-triggered skin conditions · Drug development
Regeneron secures approval for ultra-rare bone disorder drug · Drug development
Khartis Therapeutics Secures $50M Series B for Thyroid Eye Disease Treatment · Drug development
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “BioMarin does another small deal to get early-stage bone disease asset.” Browse more stories.